The First Subject Has Been Administrated Successfully with Huaota Anti-CD137 mAb For Phase I Clinical Trial in China

Today, a patient of Shanghai Chest Hospital, as the first subject, was administrated with HOT-1030, a recombinant humanized IgG1 type anti-CD137 (also known as 4-1BB) monoclonal ant...

Media Focus

Exclusive Interview | Huaota CEO Dr. Zhu Xiangyang:

Entering the 21st century, tumor immunotherapy has made great progress, especially the highly anticipated Entering the 21st century, tumor immunotherapy has made great progress, esp...

Media Focus

Huahai Pharmaceutical submitted IND application for PDL1/VEGF Bispecific Antibody

On November 24th2020, the IND application submitted for PD-L1/VEGF bispecific antibody HB0025 by Huabo Biopharm, a subsidiary of Zhejiang Huahai Pharmaceutical, was accepted by NMPA...

Media Focus

Enmorehealthcare Bioindustry Information

On January 27th2021, Shanghai Huaota Biopharmaceutical Co., Ltd. joins the BIO100+ enterprise service platform under Enmorehealthcare. Enmorehealthcare will provide Huaota with a fu...

Media Focus

Huahai Pharmaceuticals Transferred Bevacizumab Analog Project to Junshi Biosciences for ￥90 Million

On June 24 Huahai Pharmaceuticals announced that, its subsidiary Shanghai Huaota Biopharmaceutical Co., Ltd. (aka ‘Huaota’) signed the ‘Drug Technology Transfer and Cooperative Deve...

Media Focus

Dr. Zhu Xiangyang: In 2021, Huaota will start independent financing and focus on promoting clinical projects

Looking back on 2020 and looking forward to 2021, we invite the most representative industry leaders in the bio-industry, Let's listen to their new year's dearest voice!This...

Media Focus